+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Liquid Biopsy Market, Size, Forecast 2022-2027, Industry Trends, Growth, Outlook, Impact of COVID-19, Opportunity Company Analysis

  • PDF Icon

    Report

  • 170 Pages
  • March 2022
  • Region: Global
  • Renub Research
  • ID: 5562682
Global Liquid Biopsy Market will reach US$ 8.1 Billion by 2027. Over the last decades, the vision of precision treatment has dramatically revitalized the field of medical oncology; the introduction of patient-tailored therapies has particularly enhanced all measurable outcomes. Liquid biopsy is a revolutionary technique that opens previously unexpected perspectives. Thus, Liquid biopsy is a non-invasive, convenient, fast, and reproducible sampling method that can reflect the changes in tumor gene manifestation profile and provide a strong base for individualized therapy and early cancer diagnosis. Furthermore, liquid biopsy clinical applications have focused on monitoring tumor progression, screening early cancer assessing therapeutic reaction & clinical prognosis, and detecting recurrent & refractory tumors. In addition, the liquid biopsy market is categorized into Kits & Consumables, Instruments, and Services.



Worldwide Liquid Biopsy Market Size was US$ 3 Billion in 2021


The liquid biopsy industry is experiencing growth due to an increased number of cancer patients, advancements such as next-generation sequencing for cancer patients in liquid biopsies, and improved patient preference for minimally invasive therapies. Besides, an upsurge in healthcare expenditure in developing countries, such as China and India, and liquid biopsy tests to treat rare cancers are anticipated to present ample opportunities for market growth. According to the publisher Analysis, Global Liquid Biopsy Market will grow with 18% CAGR from 2021 - 2027.

COVID-19 Impact on Growth Trends of Liquid Biopsy Industry


The coronavirus disease has spread globally. Consequently, governments have assessed several rules and lockdowns worldwide, owing to an expansion in the number of coronavirus patients, affecting the market growth in the initial phase of the forecast period. This has resulted in the break of earlier diagnosis programs. Further, there has been a decrease in visits, therapies, screenings, and surgeries related to cancer, resulting in an increase in cancer morbidity in 2020. The pandemic has also affected the logistics and supplies of cancer diagnostic components, raw materials, and other essential commodities utilized in the production of liquid biopsy. These aspects restrict the growth of the liquid biopsy market during the COVID-19.

European Liquid Biopsy Market is rising due to the high Cases of Cancer


Geographically, liquid biopsy market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and LAMEA. The European liquid biopsy market is rising due to the high incidence of cancer and increasing medical costs. Consequently, the region is anticipated to multiply concerning the development and use of liquid biopsy techniques. Nowadays, in Europe, research and development on cancer diagnosis focus on liquid biopsy. Market participants and research institutes conduct extensive clinical trials to develop a sensitive liquid biopsy platform.

Lung Cancer Liquid Biopsy & Circulating Tumor DNA is anticipated to Dominate


On the basis of cancer type, the liquid biopsy market is classified into Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, and Others. Lung cancer is anticipated to dominate the liquid biopsy market due to the increased prevalence of non-small cell lung cancer globally. For instance, as per the (WHO) World Health Organization, lung cancer is by far the highest cause of cancer death among female and male, estimated to have around 1.80 Million deaths worldwide in 2020.

Based on Circulating Biomarkers, the liquid biopsy industry includes Circulating Tumor cell (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vesicles (EVs), Other Biomarkers (cell-free DNA, etc.). In recent years, the circulating tumor cell segment has been increased due to the expanded number of clinically imperative tests with genomic analyses. Additionally, circulating tumor DNA is anticipated to be the fastest-growing segment during the forecast period, owing to the rapid development of (NGS) next-generation sequencing technologies in liquid biopsy advancements applied to circulating tumor DNA (ctDNA).

Competitive Landscape


The global liquid biopsy market is highly fragmented into players like Thermo Fisher Scientific, Inc, Guardant Health, Inc, EXACT Sciences Corp, Illumina Inc., Bio - Rad Laboratories, Biocept, NeoGenomics, Inc., Qiagen NV.

This report titled Liquid Biopsy Market Global Forecast by Regions (Europe, North America, Asia-Pacific Latin America, and Middle East/Africa),Cancer (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer & Others), Product (Kits & Consumables, Instruments and Services), Sample (Plasma/Serum, Urine & Others), Circulating Biomarkers (Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) & Exosomes), Clinical Application (Monitoring, Theranostics, Prognosis & Screening), Companies (Thermo Fisher Scientific, Inc, Guardant Health, Inc, EXACT Sciences Corp, Illumina Inc., Bio - Rad Laboratories, Biocept, NeoGenomics, Inc., Qiagen NV) Provides comprehensive details about Liquid Biopsy Industry

Region - Market has been covered from 5 viewpoints


1. North America
2. Europe
3. Asia - Pacific
4. Latin America
5. Middle East & Africa

Cancer - Market has been covered from 5 viewpoints


1. Lung Cancer
2. Breast Cancer
3. Colorectal Cancer
4. Prostate Cancer
5. Others

Product - Market has been covered from 3 viewpoints


1. Kits & Consumables
2. Instruments
3. Services

Circulating Biomarkers - Market has been covered from 4 viewpoints


1. Circulating Tumor cell (CTCs)
2. Circulating Tumor DNA (ctDNA)
3. Extracellular Vesicles (EVs)
4. Other Biomarkers (cell free DNA, etc)

Clinical Application - Market has been covered from 4 viewpoints


1. Monitoring
2. Prognosis
3. Theranostics
4. Screening

Sample - Market has been covered from 3 viewpoints


1. Plasma / Serum
2. Urine
3. Others

All companies have been covered into 3 viewpoints


  • Overviews
  • Recent Developments
  • Revenues

Company Analysis


1. Thermo Fisher Scientific, Inc
2. Guardant Health, Inc
3. EXACT Sciences Corp
4. Illumina Inc.
5. Bio - Rad Laboratories
6. Biocept
7. NeoGenomics, Inc.
8. Qiagen NV.
Frequently Asked Questions about the Global Liquid Biopsy Market

What is the estimated value of the Global Liquid Biopsy Market?

The Global Liquid Biopsy Market was estimated to be valued at $3 Billion in 2021.

What is the growth rate of the Global Liquid Biopsy Market?

The growth rate of the Global Liquid Biopsy Market is 18.0%, with an estimated value of $8.1 Billion by 2027.

What is the forecasted size of the Global Liquid Biopsy Market?

The Global Liquid Biopsy Market is estimated to be worth $8.1 Billion by 2027.

Who are the key companies in the Global Liquid Biopsy Market?

Key companies in the Global Liquid Biopsy Market include Thermo Fisher Scientific, Inc, Guardant Health, Inc, EXACT Sciences Corp, Illumina Inc., Bio – Rad Laboratories, Biocept, NeoGenomics, Inc. and Qiagen NV..

Table of Contents

1. Introduction2. Research & Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global - Liquid Biopsy Market
6. Market Share - Global Liquid Biopsy
6.1 By Region
6.2 By Cancer
6.3 By Product
6.4 By Circulating Biomarkers
6.5 By Sample
7. Region - Liquid Biopsy Market
7.1 North America
7.2 Europe
7.3 Asia - Pacific
7.4 Latin America
7.5 Middle East & Africa
8. Cancer - Liquid Biopsy Market
8.1 Lung Cancer
8.2 Breast Cancer
8.3 Colorectal Cancer
8.4 Prostate Cancer
8.5 Others
9. Product - Liquid Biopsy Market
9.1 Kits & Consumables
9.2 Instruments
9.3 Services
10. Circulating Biomarkers - Liquid Biopsy Market
10.1 Circulating Tumor cell (CTCs)
10.2 Circulating Tumor DNA (ctDNA)
10.3 Extracellular Vesicles (EVs)
10.4 Other Biomarkers (cell free DNA, etc)
11. Clinical Application - Liquid Biopsy Market
11.1 Monitoring
11.2 Prognosis
11.3 Theranostics
11.4 Screening
12. Sample - Liquid Biopsy Market
12.1 Plasma / Serum
12.2 Urine
12.3 Others
13. Porters Five Forces
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14. Company Analysis
14.1 Thermo Fisher Scientific, Inc
14.1.1 Overview
14.1.2 Recent Development
14.1.3 Financial Insights
14.2 Guardant Health Inc
14.2.1 Overview
14.2.2 Recent Development
14.2.3 Financial Insights
14.3 EXACT Sciences Corp.
14.3.1 Overview
14.3.2 Recent Development
14.3.3 Financial Insights
14.4 Illumina Inc.
14.4.1 Overview
14.4.2 Recent Development
14.4.3 Financial Insights
14.5 Bio - Rad Laboratories
14.5.1 Overview
14.5.2 Recent Development
14.5.3 Financial Insights
14.6 Biocept
14.6.1 Overview
14.6.2 Recent Development
14.6.3 Financial Insights
14.7 NeoGenomics, Inc.
14.7.1 Overview
14.7.2 Recent Development
14.7.3 Financial Insights
14.8 Qiagen NV
14.8.1 Overview
14.8.2 Recent Development
14.8.3 Financial Insights
List Of Figures:
Figure 01: Global - Liquid Biopsy Market (Million US$), 2016 - 2021
Figure 02: Global - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
Figure 03: North America - Liquid Biopsy Market (Million US$), 2016 - 2021
Figure 04: North America - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
Figure 05: Europe - Liquid Biopsy Market (Million US$), 2016 - 2021
Figure 06: Europe - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
Figure 07: Asia - Pacific - Liquid Biopsy Market (Million US$), 2016 - 2021
Figure 08: Asia - Pacific - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
Figure 09: Latin America - Liquid Biopsy Market (Million US$), 2016 - 2021
Figure 10: Latin America - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
Figure 11: Middle East & Africa - Liquid Biopsy Market (Million US$), 2016 - 2021
Figure 12: Middle East & Africa - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
Figure 13: Lung Cancer - Liquid Biopsy Market (Million US$), 2016 - 2021
Figure 14: Lung Cancer - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
Figure 15: Breast Cancer - Liquid Biopsy Market (Million US$), 2016 - 2021
Figure 16: Breast Cancer - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
Figure 17: Colorectal Cancer - Liquid Biopsy Market (Million US$), 2016 - 2021
Figure 18: Colorectal Cancer - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
Figure 19: Prostate Cancer - Liquid Biopsy Market (Million US$), 2016 - 2021
Figure 20: Prostate Cancer - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
Figure 21: Others - Liquid Biopsy Market (Million US$), 2016 - 2021
Figure 22: Others - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
Figure 23: Product - Kits & Consumables Market (Million US$), 2016 - 2021
Figure 24: Product - Forecast for Kits & Consumables Market (Million US$), 2022 - 2027
Figure 25: Product - Instruments Market (Million US$), 2016 - 2021
Figure 26: Product - Forecast for Instruments Market (Million US$), 2022 - 2027
Figure 27: Product - Services Market (Million US$), 2016 - 2021
Figure 28: Product - Forecast for Services Market (Million US$), 2022 - 2027
Figure 29: Circulating Biomarkers - Circulating Tumor cell (CTCs) Market (Million US$), 2016 - 2021
Figure 30: Circulating Biomarkers - Forecast for Circulating Tumor cell (CTCs) Market (Million US$), 2022 - 2027
Figure 31: Circulating Biomarkers - Circulating Tumor DNA (ctDNA) Market (Million US$), 2016 - 2021
Figure 32: Circulating Biomarkers - Forecast for Circulating Tumor DNA (ctDNA) Market (Million US$), 2022 - 2027
Figure 33: Circulating Biomarkers - Extracellular Vesicles (EVs) Market (Million US$), 2016 - 2021
Figure 34: Circulating Biomarkers - Forecast for Extracellular Vesicles (EVs) Market (Million US$), 2022 - 2027
Figure 35: Circulating Biomarkers - Other Biomarkers (cell free DNA, etc) Market (Million US$), 2016 - 2021
Figure 36: Circulating Biomarkers - Forecast for Other Biomarkers (cell free DNA, etc) Market (Million US$), 2022 - 2027
Figure 37: Clinical Application - Monitoring Market (Million US$), 2016 - 2021
Figure 38: Clinical Application - Forecast for Monitoring Market (Million US$), 2022 - 2027
Figure 39: Clinical Application - Prognosis Market (Million US$), 2016 - 2021
Figure 40: Clinical Application - Forecast for Prognosis Market (Million US$), 2022 - 2027
Figure 41: Clinical Application - Theranostics Market (Million US$), 2016 - 2021
Figure 42: Clinical Application - Forecast for Theranostics Market (Million US$), 2022 - 2027
Figure 43: Clinical Application - Screening Market (Million US$), 2016 - 2021
Figure 44: Clinical Application - Forecast for Screening Market (Million US$), 2022 - 2027
Figure 45: Sample - Plasma / Serum Market (Million US$), 2016 - 2021
Figure 46: Sample - Forecast for Plasma / Serum Market (Million US$), 2022 - 2027
Figure 47: Sample - Urine Market (Million US$), 2016 - 2021
Figure 48: Sample - Forecast for Urine Market (Million US$), 2022 - 2027
Figure 49: Sample - Others Market (Million US$), 2016 - 2021
Figure 50: Sample - Forecast for Others Market (Million US$), 2022 - 2027
Figure 51: Thermo Fisher Scientific, Inc - Global Revenue (Million US$), 2016 - 2021
Figure 52: Thermo Fisher Scientific, Inc - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 53: Guardant Health , Inc - Global Revenue (Million US$), 2016 - 2021
Figure 54: Guardant Health , Inc - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 55: EXACT Sciences Corp. - Global Revenue (Million US$), 2016 - 2021
Figure 56: EXACT Sciences Corp. - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 57: Illumina Inc. - Global Revenue (Million US$), 2016 - 2021
Figure 58: Illumina Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 59: Bio - Rad Laboratories - Global Revenue (Million US$), 2016 - 2021
Figure 60: Bio - Rad Laboratories - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 61: Biocept - Global Revenue (Million US$), 2016 - 2021
Figure 62: Biocept - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 63: NeoGenomics, Inc. - Global Revenue (Million US$), 2016 - 2021
Figure 64: NeoGenomics, Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 65: Qiagen NV - Global Revenue (Million US$), 2016 - 2021
Figure 66: Qiagen NV - Forecast for Global Revenue (Million US$), 2022 - 2027
List Of Tables:
Table 01: Global - Liquid Biopsy Market Share by Region (Percent), 2016 - 2021
Table 02: Global - Forecast for Liquid Biopsy Market Share by Region (Percent), 2022 - 2027
Table 03: Global - Liquid Biopsy Market Share by Cancer (Percent), 2016 - 2021
Table 04: Global - Forecast for Liquid Biopsy Market Share by Cancer (Percent), 2022 - 2027
Table 05: Global - Liquid Biopsy Market Share by Product (Percent), 2016 - 2021
Table 06: Global - Forecast for Liquid Biopsy Market Share by Product (Percent), 2022 - 2027
Table 07: Global - Liquid Biopsy Market Share by Circulating Biomarkers (Percent), 2016 - 2021
Table 08: Global - Forecast for Liquid Biopsy Market Share by Circulating Biomarkers (Percent), 2022 - 2027
Table 09: Global - Liquid Biopsy Market Share by Sample (Percent), 2016 - 2021
Table 10: Global - Forecast for Liquid Biopsy Market Share by Sample (Percent), 2022 - 2027

Companies Mentioned

  • Thermo Fisher Scientific, Inc
  • Guardant Health, Inc
  • EXACT Sciences Corp
  • Illumina Inc.
  • Bio – Rad Laboratories
  • Biocept
  • NeoGenomics, Inc.
  • Qiagen NV.

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...